Abstract:Parkinson’s disease arises from the demise of dopaminergic neurons in the substantia nigra resulting from both environmental and hereditary factors. Drug interventions can solely delay disease progression, but cannot provide a cure. Therefore, cell replacement therapy may represent a promising treatment approach. Although the United States has already employed this technology, independent clinical and preclinical trials are mandatory for its inclusion in Russia. The iPSC technology enables the acquisition of personalized iPSC lines for each patient, nearly eradicating the immune response. While autologous cell therapy is theoretically ideal, the reprogramming of patient cells into iPSCs and subsequent differentiation for each patient incurs time and cost. Alternatively, differentiated derivatives of low immunogenic iPSCs, lacking HLA class I expression, can serve as a substitute. These cells evade the T-cell immune response, but other minor HLAs and cells from the innate immune system, like macrophages and NK cells, could still participate in the immune response’s development, although not as potent as in allogeneic transplantation. While these cell products don’t escape the immune response entirely, they lessen it significantly, potentially enabling the use of less severe immunosuppressive therapy. In this study, a protocol previously established in the cell biology laboratory was used to differentiate iPSCs lacking HLA class I expression and wild-type iPSCs into midbrain dopaminergic neuron precursors. A thorough analysis of the forerunners was performed and demonstrated appropriate patterning. The progenitors were then implanted into the brains of rats with 6-OHDA-induced Parkinsonism and followed for 6 months to compare their in vivo differentiation to standard differentiation in vitro. In addition, the systemic inflammatory response of the animals to the transplantation and the biodistribution of the injected cells were investigated. The literature inadequately addresses the question of which cells, other than dopaminergic neurons, differentiate during in vivo graft differentiation and potentially cause side effects in cell therapy. The literature suggests that only approximately 3% of transplanted cells differentiate into dopaminergic neurons, which is adequate to improve motor function in model animals. We found that a significant proportion of the progenitors differentiate into glial cells. The dynamics of maturation of transplanted neurons was evaluated. Thus, we approached preclinical testing of the cell product after having characterized in detail the dynamics of maturation and the composition of the graft. Comparison of in vivo and in vitro differentiation will allow evaluation of the quality of cellular material for transplantation.

Treatment of Parkinson's disease model mice with allogeneic embryonic stem cells: necessity of immunosuppressive treatment for sustained improvement

Effects of neural cells transplantation on rat model of Parkinson's disease

Efficacy of Tyrosine Hydroxylase gene modified neural stem cells derived from bone marrow on Parkinson's disease--a rat model study.

Distinct Efficacy of Pre-Differentiated Versus Intact Fetal Mesencephalon-Derived Human Neural Progenitor Cells in Alleviating Rat Model of Parkinson’s Disease

The Therapeutic Effect of Intracerebral Transplantation of Superparamagnetic Iron Oxide and Enhanced Fluorescence Protein Double Labeled Mescencephalic Neural Stem Cells in Rat Model of Parkinson's Disease

Therapeutic Potential of Repeated Intravenous Transplantation of Human Adipose-Derived Stem Cells in Subchronic MPTP-Induced Parkinson’s Disease Mouse Model

Survival and Differentiation of Transplanted Neural Stem Cells in Mice Brain with MPTP-induced Parkinson Disease.

Dopaminergic precursors differentiated from human blood-derived induced neural stem cells improve symptoms of a mouse Parkinson's disease model

Transplantation of human neural stem cell prevents symptomatic motor behavior disability in a rat model of Parkinson's disease

Transplantation of Human Neural Stem Cell Prevents Symptomatic Motor Behavior Disability in a Rat Model of Parkinson’s Disease

Transplantation of Human Neural Stem Cells in a Parkinsonian Model Exerts Neuroprotection Via Regulation of the Host Microenvironment

Grafted neural stem cells migrate to substantia nigra and improve behavior in Parkinsonian rats

Intracerebral Transplantation of Differentiated Human Embryonic Stem Cells to Hemiparkinsonian Monkeys.

The effect of intracerebral transplanted conditional immortalized neural stem cells modified to express tyrosine hydroxylase gene on rotational behavior and dopamine metabolism in rodents with Parkin's disease

The Therapeutic Effects of Tyrosine Hydroxylase Gene Transfected Hematopoetic Stem Cells in a Rat Model of Parkinson’s Disease

Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson's disease

Autologous Transplant Therapy Alleviates Motor and Depressive Behaviors in Parkinsonian Monkeys.

The fate of iPSCs-derived low immunogenic dopaminergic neuron precursors after transplantation into the striatum of rats with 6-OHDA-induced parkinsonism

Co-Transplantation of Gdnf-Overexpressing Neural Stem Cells and Fetal Dopaminergic Neurons Mitigates Motor Symptoms in A Rat Model of Parkinson'S Disease

Migration and Differentiation of Mesenchymal Stem Cells Labeled with Enhanced Green Fluorescent Protein in the Parkinson's Disease Rat Brain

In Vivo Visualization and Monitoring of Viable Neural Stem Cells Using Noninvasive Bioluminescence Imaging in the 6-Hydroxydopamine-Induced Mouse Model of Parkinson Disease